Neurogene Inc. Cash and Restricted Cash
Neurogene Inc. (NGNE) had Cash and Restricted Cash of $112.82 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $112.82M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $124.50M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $104.18M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $71.34M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $112.82M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $124.50M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $104.18M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $71.34M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $59.15M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $71.11M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $136.93M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $66.97M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $111.37M 10-Q · filed 2025-08-11 | |
| 2024-03-31 | $150.48M 10-Q · filed 2025-05-09 | |
| 2023-12-31 | $148.72M 10-K · filed 2026-03-24 | |
| 2023-09-30 | $45.56M 10-Q · filed 2024-11-18 | $25.73M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $59.05M 10-Q · filed 2024-08-09 | $31.62M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $68.54M 10-Q · filed 2024-05-10 | $36.37M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $82.02M 10-K · filed 2025-03-24 | $38.77M 10-K · filed 2023-03-20 |
| 2022-09-30 | $41.21M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $78.40M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $128.94M 10-Q · filed 2023-05-08 | |
| 2021-12-31 | $70.54M 10-K · filed 2024-03-18 | $143.34M 10-K · filed 2022-03-01 |
| 2021-09-30 | $155.80M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $165.11M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $179.27M 10-Q · filed 2022-05-09 | |
| 2020-12-31 | $193.43M 10-K · filed 2023-03-20 | |
| 2020-09-30 | $202.03M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $130.47M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $139.93M 10-Q · filed 2021-05-12 | |
| 2019-12-31 | $143.09M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $66.31M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $72.70M 10-Q · filed 2020-08-12 | |
| 2019-03-31 | $74.17M 10-Q · filed 2020-05-06 | |
| 2018-12-31 | $76.93M 10-K · filed 2021-03-25 | |
| 2018-09-30 | $86.73M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $99.13M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $66.61M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $52.03M 10-K · filed 2020-03-12 | |
| 2017-09-30 | $47.10M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $27.15M 10-Q · filed 2018-08-08 | |
| 2016-12-31 | $32.30M 10-K · filed 2020-03-12 | |
| 2015-12-31 | $39.53M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |